{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.31","upperLimit":"12.62","value":"9.53"},{"groupId":"OG001","lowerLimit":"6.08","upperLimit":"20.27","value":"12.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"<1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.95","upperLimit":"14.52","value":"10.22"},{"groupId":"OG001","lowerLimit":"6.74","upperLimit":"13.34","value":"9.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"PD-L1: ≥ 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.26","upperLimit":"11.37","value":"9.95"},{"groupId":"OG001","lowerLimit":"6.28","upperLimit":"14.78","value":"8.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"title":"PD-L1: < 25%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.43","upperLimit":"48.69","value":"5.78"},{"groupId":"OG001","lowerLimit":"7.03","upperLimit":"16.66","value":"10.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"PD-L1: ≥ 25%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.51","upperLimit":"11.37","value":"9.76"},{"groupId":"OG001","lowerLimit":"6.74","upperLimit":"14.26","value":"10.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"PD-L1: <50%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.43","upperLimit":"48.69","value":"26.02"},{"groupId":"OG001","lowerLimit":"1.51","upperLimit":"16.66","value":"7.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"PD-L1: > 50%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.98","upperLimit":"14.32","value":"10.32"},{"groupId":"OG001","lowerLimit":"4.86","upperLimit":"17.51","value":"7.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"PD-L1: 1 - < 25%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.71","upperLimit":"14.16","value":"6.93"},{"groupId":"OG001","lowerLimit":"7.56","upperLimit":"44.88","value":"28.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Without quantifiable PD-L1 expression at baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.\n\nTumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Refractory Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Refractory Subgroup"}],"paramType":"MEDIAN","populationDescription":"Platinum refractory subgroup","reportingStatus":"POSTED","timeFrame":"From randomization to death. Approximately 63 Months","title":"Overall Survival (OS) - Platinum Refractory Subgroup Based on PD-L1 Status","type":"SECONDARY","unitOfMeasure":"Months"}